287 related articles for article (PubMed ID: 14525889)
1. "Polypill" to fight cardiovascular disease: cost effectiveness of statins for primary prevention of cardiovascular events is questionable.
Messori A; Santarlasci B; Trippoli S; Vaiani M
BMJ; 2003 Oct; 327(7418):808-9; discussion 809; author reply 809-10. PubMed ID: 14525889
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
3. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
4. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
5. Statins for cardiovascular prevention according to different strategies: a cost analysis.
Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
van Hout BA; Simoons ML
Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
[TBL] [Abstract][Full Text] [Related]
7. Prescribing statins in general practice: who decides?
Steel N; Fleetcroft B; Hassan Y
Br J Gen Pract; 2017 Jun; 67(659):246-247. PubMed ID: 28546390
[No Abstract] [Full Text] [Related]
8. Statins for primary prevention of cardiovascular disease.
Deckers JW; Blumenthal RS
BMJ; 2011 Feb; 342():d1048. PubMed ID: 21325384
[No Abstract] [Full Text] [Related]
9. Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma.
Aronow WS
J Am Geriatr Soc; 2009 Oct; 57(10):1942-3; author reply 1943-4. PubMed ID: 19807799
[No Abstract] [Full Text] [Related]
10. The polypill to prevent cardiovascular disease: physicians' perspectives.
Viera AJ
Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
Ohsfeldt RL; Gandhi SK; Smolen LJ; Jensen MM; Fox KM; Gold A; Hsia J
J Med Econ; 2010; 13(3):428-37. PubMed ID: 20662625
[TBL] [Abstract][Full Text] [Related]
12. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
Sigvant B; Henriksson M; Lundin F; Wahlberg E
Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of statins in older adults: further evidence that less is more.
Rich MW
Ann Intern Med; 2015 Apr; 162(8):590-1. PubMed ID: 25894030
[No Abstract] [Full Text] [Related]
14. Cost and effectiveness of cardiovascular prevention.
Boyar A
Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Martens LL; Guibert R
Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
[TBL] [Abstract][Full Text] [Related]
16. [Statins in primary prevention - a must for the general practitioner?].
Zoller M
Praxis (Bern 1994); 2011 Jul; 100(14):859-60. PubMed ID: 21732299
[No Abstract] [Full Text] [Related]
17. Statins for primary prevention in older adults.
Ann Intern Med; 2015 Apr; 162(8):I-28. PubMed ID: 25894041
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
Slejko JF; Page RL; Sullivan PW
Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
[TBL] [Abstract][Full Text] [Related]
19. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
20. Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials.
Trifirò G; Alacqua M; Corrao S; Tari M; Arcoraci V
J Am Geriatr Soc; 2008 Jan; 56(1):175-7. PubMed ID: 18184214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
